Table 2 Association between E-DII from food plus supplement and all-causes mortality risk among 1064 breast cancer cases in the PLCO Cancer Screening Trial.

From: Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study

Tertile of E-DII score

Death from any cause (n)

Person-years

Hazard ratio (95% confidence interval)

Modela

Mode2b

Tertile 1 (−7.8, −5.6)

86

4942

1.00 (reference)

1.00 (reference)

Tertile 2 (−5.6, −4.1)

98

4888

1.14 [0.85, 1.52]

1.16 [0.87, 1.56]

Tertile 3 (−4.1, 4.9)

112

4477

1.58 [1.19, 2.09]

1.34 [1.01, 1.81]

Ptrend

  

0.002

0.049

Per 1-unit DII increment

296

14,307

1.10 [1.04, 1.17]

1.06 [1.00, 1.13]

After excluding cases with less 1 year from breast cancer diagnosis to DHQ completionc

 Tertile 1 (−7.8, −5.6)

17

3400

1.00 (reference)

1.00 (reference)

 Tertile 2 (−5.6, −4.1)

15

3280

0.89 [0.45, 1.76]

0.99 [0.73, 2.05]

 Tertile 3 (−4.1, 4.9)

25

2691

1.66 [0.90, 3.05]

2.20 [1.14, 4.25]

 Ptrend

  

0.08

0.03

 Per 1-unit DII increment

172

9371

1.21[1.08, 1.35]

1.21 [1.06, 1.39]

  1. aAdjusted for age of breast cancer diagnosis (continues) and total energy intake (continues, kcal/day).
  2. bStratified by age of breast cancer diagnosis (≤60 years old, >60 years old), years from breast cancer diagnosis to DHQ completion (≤1 year, >1 year), stage (0/I, II/III) due to PH assumption violation and adjusted for total energy intake (continues, kcal/day), body mass index (continues, kg/m2), trial arm (control, intervention), race (white, black, others), marital status (single, married, divorced or separated, widowed), income(<$20,000, $20,000–$49,000, $50,000–$99,000, $100,000–$200,000, <$200,000), educational level (less than high school, high school graduate or equivalent, post-high school education, college education or higher), smoking status (never smoked, past smoked, current smoked), hormone replacement therapy (never used, former used, current used), history of diabetes (no, yes), physical activity (active less than one time per month, active at least one time per month), estrogen receptor status (negative, positive), and progesterone receptor status (negative, positive).
  3. cModel included 610 cases and was adjusted for covariates listed in b except years from breast cancer diagnosis to DHQ completion.
Back to article page